With a strong geographical presence and revenue of €4.7 billion in 2021 achieved in 150 countries, Servier employs 21,800 people worldwide.
Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative partnerships with academic institutions, other pharmaceutical groups, and biotech companies. It also integrates the patient’s needs at the heart of its activities, from research to support beyond the pill.
As a leader in cardiology, the ambition of the Servier Group is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.